Composition containing ionic liquid and component to be delivered for use in combination with iontophoresis, and use thereof
A composition of a carboxylic acid and organic amine salt applied with iontophoresis improves the delivery efficiency of target components to the skin, overcoming the limitations of existing methods by enhancing transdermal penetration.
Patent Information
- Application Number
- PCT/JP2026/017278
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-04-30
- Publication Date
- 2026-11-12
AI Technical Summary
Existing methods for delivering target substances to the skin, such as ionic liquids and iontophoresis, do not effectively enhance the delivery efficiency of components like peptides and proteins, which have high molecular weights and are difficult to penetrate the skin.
A composition containing a salt formed by a carboxylic acid compound and an organic amine compound is applied to the skin, followed by iontophoresis, to improve the delivery efficiency of target components.
The combination significantly enhances the transdermal penetration of target components, allowing them to reach deeper skin layers, including blood and muscle layers, compared to using ionic liquids or iontophoresis alone.
Smart Images

Figure JP2026017278_12112026_PF_FP_ABST
Abstract
Description
Compositions containing ionic liquids and delivered components for use in combination with iontophoresis, and their applications.
[0001] This invention relates to compositions containing ionic liquids and delivered components for use in combination with iontophoresis, and to the use thereof.
[0002] Conventionally, various methods have been known to promote the delivery of target substances (components to be delivered) to the skin. One example of such a method is the use of an ionic liquid. For example, Patent Document 1 describes a composition comprising an ionic liquid and a poorly absorbed drug, wherein the ionic liquid consists of anions and cations, the anions being organic acids having 3 to 7 carbon atoms, and the cations being selected from the group consisting of arginine, meglumine, trometamol, and diethanolamine. It has been reported that the absorption of poorly absorbed drugs was significantly improved by using this ionic liquid.
[0003] Furthermore, other methods to promote the delivery of target substances to the skin include physical methods such as electroporation and iontophoresis. Electroporation is a method in which transient perforations are formed in the cell membrane by applying a high-voltage pulse, and the target component is delivered into the cell through these perforations. Iontophoresis is a method in which a target substance is delivered into the skin by applying a weak electric current to the skin. For example, Patent Document 2 describes a skin electroconducting composition for use on skin that is immersed in an electrolyte solution through which a weak electric current is passed, characterized in that it is a hydrogel composition containing a water-soluble polymer and a useful component, and it has been reported that the useful component could be effectively delivered into the skin by immersing skin that has been in contact with the hydrogel composition containing a water-soluble polymer and a useful component in an electrolyte solution through which a weak electric current is passed.
[0004] International Publication No. 2022 / 173006, Japanese Patent Publication No. 2024-98727
[0005] Thus, although various methods have been considered to promote the delivery of target substances to the skin, providing new means to promote the delivery of target substances to the skin remains important today.
[0006] The objective is to provide a novel means for promoting the delivery of target components to the skin.
[0007] As a result of diligent research, the inventors have found that applying a composition obtained by mixing an ionic liquid and a target component to the skin and then performing iontophoresis on the skin can improve the delivery of the target component to the skin. In particular, as mentioned above, ionic liquids and iontophoresis are known as methods that can improve the delivery of a target component to the skin, but the inventors have found that applying a composition obtained by mixing an ionic liquid and a target component to the skin and then performing iontophoresis significantly improves the delivery efficiency of the target component to the skin compared to using only an ionic liquid or only iontophoresis. The present invention was completed by further research based on this finding, and this disclosure includes, for example, the inventions described below.
[0008] Item 1. A composition containing an ionic liquid and a component to be delivered for use in combination with iontophoresis, wherein the ionic liquid is a salt composed of a carboxylic acid compound and an organic amine compound. Item 2. The composition according to Item 1, wherein the carboxylic acid compound is at least one selected from the group consisting of hydroxy acids having 3 to 7 carbon atoms, aliphatic monocarboxylic acids having 4 to 20 carbon atoms, keto acids having 3 to 7 carbon atoms, aromatic monocarboxylic acids having 6 to 12 carbon atoms, dicarboxylic acids having 3 to 9 carbon atoms, and tricarboxylic acids having 6 to 12 carbon atoms, and the organic amine compound is an alkanolamine having 2 to 9 carbon atoms. Item 3. The composition according to Item 1 or 2, wherein the carboxylic acid compound is at least one selected from the group consisting of lactic acid, sorbic acid, capric acid, lauric acid, myristic acid, stearic acid, isostearic acid, oleic acid, salicylic acid, and levulinic acid. Item 4. A method for delivering a target component to the skin by iontophoresis, comprising the following steps: preparing a composition containing an ionic liquid and the target component, applying the composition so as to be in contact with the skin, and delivering the target component into the skin by passing a weak electric current through the skin, wherein the ionic liquid is a salt composed of a carboxylic acid compound and an organic amine compound. Item 5. A method for electrotherapy of the skin, comprising the following steps: passing a weak electric current through skin to which a composition containing an ionic liquid and the target component has been applied by iontophoresis, wherein the ionic liquid is a salt composed of a carboxylic acid compound and an organic amine compound.
[0009] This disclosure provides a novel method for improving the delivery of target components to the skin by combining ionic liquids with iontophoresis. According to this disclosure, the transdermal penetration of target components can be improved.
[0010] The results of Test Example 1 (without iontophoresis) are shown. The results of Test Example 1 (with iontophoresis) are shown. The results of Test Example 2 are shown. The results of Test Example 3 are shown. The results of Test Example 3 are shown. The results of Test Example 3 are shown. The results of Test Example 3 are shown. The results of Test Example 4 are shown. The results of Test Example 4 are shown. The results of Test Example 4 are shown. The results of Test Example 5 are shown. The results of Test Example 5 are shown. The results of Test Example 5 are shown. The results of Test Example 6 are shown. The results of Test Example 7 are shown. The results of Test Example 7 are shown. The results of Test Example 8 are shown. The results of Test Example 8 are shown. The results of Test Example 9 are shown. The results of Test Example 9 are shown. The results of Test Example 10 are shown. The results of Test Example 10 are shown. The results of Test Example 11 are shown.
[0011] The embodiments included in this disclosure are described in further detail below. In this disclosure, “contains” also means “substantially consists of” or “consists of.”
[0012] This disclosure encompasses compositions containing an ionic liquid and a delivered component for use in combination with iontophoresis, wherein the ionic liquid is a salt composed of a carboxylic acid compound and an organic amine compound. Hereinafter, such compositions may be referred to as "the compositions of this disclosure."
[0013] The compositions of the present disclosure include an ionic liquid, which is a salt composed of a carboxylic acid compound and an organic amine compound. In the present disclosure, an ionic liquid is a viscous liquid Brønsted salt formed from anions and cations at room temperature (20°C) with a melting point of 100°C or less. The ionic liquid can be prepared by mixing an carboxylic acid compound as an acid component and an organic amine compound as a base component in equimolar amounts or in excess of one of them at room temperature or under heating (usually 15 to 80°C). The excess amount of either the carboxylic acid compound or the organic amine compound is not particularly limited, but preferably 0.1 to 10 moles of the organic amine compound per mole of the carboxylic acid compound is exemplified, more preferably 0.5 to 5 moles, and even more preferably 0.8 to 2 moles.
[0014] Examples of carboxylic acid compounds include preferably hydroxy acids having 3 to 7 carbon atoms, aliphatic monocarboxylic acids having 4 to 20 carbon atoms, keto acids having 3 to 7 carbon atoms, aromatic monocarboxylic acids having 6 to 12 carbon atoms, dicarboxylic acids having 3 to 9 carbon atoms, tricarboxylic acids having 6 to 12 carbon atoms, and more preferably hydroxy acids having 2 to 5 carbon atoms, aliphatic monocarboxylic acids having 4 to 20 carbon atoms, keto acids having 3 to 5 carbon atoms, aromatic monocarboxylic acids having 6 to 12 carbon atoms, dicarboxylic acids having 3 to 9 carbon atoms, and tricarboxylic acids having 6 to 12 carbon atoms. Examples of carboxylic acid compounds that are more preferably include lactic acid, propionic acid, butyric acid, valeric acid, sorbic acid, capric acid, lauric acid, myristic acid, stearic acid, isostearic acid, oleic acid, levulinic acid, salicylic acid, gallic acid, adipic acid, maleic acid, oxalic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, phthalic acid, isophthalic acid, terephthalic acid, malic acid, sebacic acid, citric acid, etc. Furthermore, examples of particularly preferred carboxylic acid compounds include lactic acid, sorbic acid, capric acid, lauric acid, myristic acid, stearic acid, isostearic acid, oleic acid, salicylic acid, levulinic acid, etc. Carboxylic acid compounds may be used individually or in combination of two or more.
[0015] Organic amine compounds are basic components that constitute ionic liquids, and examples include alkanolamines with 2 to 9 carbon atoms, such as monoethanolamine, monoisopropanolamine, diethanolamine, diisopropanolamine, triethanolamine, triisopropanolamine, ethylenediamine, and trishydroxymethylaminomethane (trometamol). More preferably, alkanolamines with 2 to 6 carbon atoms are exemplified as organic amine compounds, and even more preferably, diisopropanolamine, triethanolamine, and triisopropanolamine are exemplified. Organic amine compounds may be used individually or in combination of two or more.
[0016] Ionic liquids may be used individually or in combination of two or more types.
[0017] The delivered component is not particularly limited as long as it is a component that you want to deliver to the skin. Examples of delivered components include peptides, proteins, nucleic acids, polysaccharides, amino acids, vitamins, inorganic compounds, organic compounds, and other antibacterial components, antiviral components, local anesthetic components, antitumor components, nucleic acid drugs, antibody drugs, diagnostic agents for diseases, hormones, diabetes drugs, antihypertensive components, nucleic acid protein complexes, anti-allergic components, moisturizing components, anti-wrinkle components, anti-inflammatory components, anti-analgesic components, antioxidant components, etc. The delivered component may be labeled as needed, and examples of such labeling include labeling components such as radioactive substances, enzymes, and fluorescent substances. For example, if the delivered component is a diagnostic agent, the behavior of the diagnostic agent can be confirmed using the labeled substance as an indicator.
[0018] In this disclosure, the molecular weight of the delivered component is not limited, but for example, a molecular weight of 10 million or less is preferably exemplified, and a molecular weight of 5 million or less is more preferably exemplified. Furthermore, the lower limit of the molecular weight of the delivered component is not limited, but for example, a molecular weight of 50 or more is preferably exemplified, more preferably 100 or more, even more preferably 500 or more, and particularly preferably 1000 or more is exemplified. As for the molecular weight, preferably 50 to 10 million is exemplified, more preferably 2 million to 5 million is exemplified, even more preferably 10 million to 3 million is exemplified, and particularly preferably 10,000 to 2 million is exemplified. In this disclosure, molecular weight means weight-average molecular weight (Mw).
[0019] The delivered component may be included as a component constituting the ionic liquid (hereinafter, the ionic liquid may be referred to as "ionic liquid 1") by forming a salt with a carboxylic acid compound or an organic amine compound. Alternatively, the delivered component may be a component constituting an ionic liquid different from ionic liquid 1 (hereinafter, the ionic liquid may be referred to as "ionic liquid 2"), although it forms a salt with a carboxylic acid compound or an organic amine compound. Therefore, the composition of this disclosure may, for example, contain one selected from ionic liquid 1 and ionic liquid 2, or it may contain both ionic liquid 1 and ionic liquid 2.
[0020] The delivered component may be used alone or in combination of two or more components.
[0021] Without limiting the present disclosure, the content of the ionic liquid in the compositions of the present disclosure may be appropriately determined depending on the type of ionic liquid, the type of component to be delivered, the form of the composition, the expected effect, etc., and is not limited to the range in which the effects of the present disclosure can be obtained, but preferably 3 to 100% by mass is exemplified, more preferably 10 to 99% by mass, and even more preferably 20 to 95% by mass is exemplified.
[0022] Furthermore, although not limiting to the present disclosure, the content of, for example, ionic liquid 1 in the composition of the present disclosure may be appropriately determined depending on the type of ionic liquid, the type of component to be delivered, the form of the composition, the expected effect, etc., and is not limited to the range in which the effects of the present disclosure can be obtained, but preferably 3 to 100% by mass is exemplified, more preferably 10 to 99% by mass, and even more preferably 20 to 95% by mass is exemplified.
[0023] Furthermore, the content of the delivered component in the composition of this disclosure may be appropriately determined depending on the type of delivered component, the type of ionic liquid, the form of the composition, the expected effect, etc., and is not limited to the range in which the effects of this disclosure can be obtained, but preferably 0.1 to 30% by mass is exemplified, more preferably 0.5 to 20% by mass, and even more preferably 1 to 10% by mass is exemplified.
[0024] Furthermore, the total content of the ionic liquid and the delivered component in the composition of this disclosure may be appropriately determined according to the type of ionic liquid, the type of delivered component, the form of the composition, the expected effect, etc., and is not limited to the range in which the effects of this disclosure can be obtained, but preferably 3 to 100% by mass is exemplified, more preferably 10 to 99.5% by mass, and even more preferably 15 to 100% by mass or 15 to 97% by mass is exemplified. When the delivered component is a component of the ionic liquid, the value of the ionic liquid content includes the content of the delivered component.
[0025] Furthermore, for example, the total content of the ionic liquid 1 and the delivered component in the composition of this disclosure may be appropriately determined according to the type of ionic liquid, the type of delivered component, the form of the composition, the expected effect, etc., and is not limited to the range in which the effects of this disclosure can be obtained, but preferably 3 to 100% by mass is exemplified, more preferably 10 to 99.5% by mass, and even more preferably 15 to 100% by mass or 15 to 97% by mass is exemplified. When the delivered component is a component of the ionic liquid 1, the value of the content of the ionic liquid 1 includes the content of the delivered component.
[0026] Furthermore, the proportion of the ionic liquid to the delivered component in the composition of this disclosure is not limited, and is not limited within the range in which the effects of this disclosure can be obtained. For every 1 part by mass of the delivered component, the ionic liquid is preferably 1 to 10,000 parts by mass, more preferably 10 to 5,000 parts by mass, and even more preferably 100 to 1,000 parts by mass.
[0027] Furthermore, for example, the ratio of ionic liquid 1 to the delivered component in the composition of this disclosure is not limited, and is not limited within the range in which the effects of this disclosure can be obtained. For example, the ionic liquid 1 is preferably 1 to 10,000 parts by mass, more preferably 10 to 5,000 parts by mass, and even more preferably 100 to 1,000 parts by mass per 1 part by mass of the delivered component.
[0028] The composition of this disclosure may be in liquid, semi-solid, or solid form. Therefore, the composition of this disclosure may be in liquid form, gel form, cream form, sheet form, ointment form, patch form, spray form, etc.
[0029] The compositions of this disclosure may contain any other components, such as pharmaceutically or cosmetically acceptable components, depending on their form, etc., as long as they do not interfere with the effects of this disclosure. Examples of other components include solvents (medium-chain triglyceride fatty acids, vegetable oils and fats, silicone oils, cocoa butter oils, etc.), excipients (lactose, cellulose, starch, magnesium stearate, water, light anhydrous silicic acid, gelling hydrocarbons, etc.), colorants, gelling agents, fragrances, stabilizers, plasticizers, solubilizers, pH adjusters, diluents, emulsifiers, dispersants, thickeners, tack enhancers, preservatives, antioxidants, surfactants, absorption enhancers, osmotic pressure adjusters, etc. Other components may be used individually or in combination of two or more, and the content of other components in the composition is not limited.
[0030] Without limiting this disclosure, medium-chain fatty acid triglycerides are given as an example of solvents among the other components mentioned above. Medium-chain fatty acid triglycerides are compounds having a structure in which three medium-chain fatty acids are ester-bonded to one glycerol molecule. The fatty acids may be saturated or unsaturated, and may be linear or branched. The number of carbon atoms in the fatty acids is also not limited, but preferably 2 to 20 carbon atoms, preferably 3 to 18 carbon atoms, etc. While not limited to these, examples of fatty acids include lactic acid, tartaric acid, citric acid, malic acid, salicylic acid, levulinic acid, capric acid (decanoic acid), oleic acid, isostearic acid, caprylic acid, etc. The three fatty acids bonded to one glycerol molecule may be the same, only two may be the same, or they may be different from each other. Medium-chain fatty acid triglycerides may be used alone or in combination of two or more.
[0031] As one embodiment of the compositions of the present disclosure, a composition containing an ionic liquid, a component to be delivered, and a medium-chain fatty acid triglyceride is exemplified. When the composition contains a medium-chain fatty acid triglyceride, the content of the medium-chain fatty acid triglyceride in the composition is preferably 3 to 97% by mass, 10 to 90% by mass, and more preferably 20 to 80% by mass.
[0032] The compositions of this disclosure can be prepared by mixing a carboxylic acid compound, an organic amine compound, and a target component, which are components of an ionic liquid, with other components as needed. Preferably, the compositions of this disclosure are prepared by mixing a carboxylic acid compound and an organic amine compound to create an ionic liquid, and then mixing the ionic liquid with the target component, with other components as needed.
[0033] The compositions of this disclosure may be applied directly to the skin (including mucous membranes) (by application, patching, spraying, immersion, etc.), or they may be applied to the skin together with a carrier capable of supporting the composition. The compositions are typically applied in contact with the skin. The amount of the compositions of this disclosure applied to the skin is not limited and can be appropriately determined depending on the type of component to be delivered, the form of the composition, the expected effect, etc. The compositions of this disclosure are preferably used as external skin compositions. The contact time of the compositions of this disclosure with the skin is not limited, but preferably 10 minutes or more is exemplified, more preferably 10 minutes to 3 hours, even more preferably 20 minutes to 2 hours, and particularly preferably 30 minutes to 1 hour.
[0034] When the composition of the present disclosure is applied to the skin together with a carrier capable of supporting the composition, the shape, material, thickness, etc. of the carrier are not limited as long as they do not impair the effects of the present disclosure. A sheet-shaped carrier is exemplified as the carrier. The composition can be applied to part or all of one side or both sides of the carrier, and the shape of the carrier may be appropriately determined in consideration of the shape, area and the like of the skin to which the composition is intended to be applied. Examples of the carrier include non-woven fabrics, woven fabrics, resin sheets, and structures (laminates and the like) obtained by arbitrarily combining these. For example, as fiber materials for non-woven fabrics and woven fabrics, natural fibers such as cotton, hemp, silk and paper, synthetic fibers such as polypropylene, polyester, polypropylene terephthalate, polyethylene, rayon and acrylic, mixed fibers of natural fibers and synthetic fibers, and the like are exemplified. For example, as the resin sheet, conventionally known resin sheets such as polypropylene sheets, polyester sheets, and polypropylene terephthalate sheets are exemplified. Further, after the composition of the present disclosure is applied to the skin, the composition may be fixed to the skin by covering part or the entire surface of the composition with a carrier, and after the composition of the present disclosure is supported on the carrier, the composition may be brought into contact with the skin to fix the composition to the skin.
[0035] The composition of the present disclosure is used in combination with iontophoresis. Iontophoresis is a technique that can be used, for example, for delivering substances to the skin, and is a technique that utilizes the electrical repulsion property of ions (the property that anions tend to move away from the cathode, and the property that cations tend to move away from the anode).
[0036] The compositions of this disclosure are not limited as long as they are used in combination with iontophoresis, and typically a weak electric current by iontophoresis is applied to the skin in contact with the composition of this disclosure. The order of contact of the composition with the skin and the application of current to the skin is inconsistent, and may be simultaneous or different. For example, the composition may be brought into contact with the skin, and then the portion of the skin in contact with the composition and / or the composition may be applied; or the composition may be brought into contact with the skin after the current has been applied; or the application of current to the skin and contact between the skin and the composition may occur simultaneously. Preferably, the application of current may be done simultaneously with or after contact of the composition with the skin. Current may be applied by directly or indirectly bringing electrodes into contact with the skin portion and / or the composition. For example, if the composition of this disclosure is liquid, the skin may be immersed in the composition and then electrodes may be brought into contact with the skin portion and / or the composition to apply current; or the skin may be immersed in the composition while it is being applied. Alternatively, the skin that has come into contact with the composition may be immersed in an electrolyte solution that can conduct electricity by iontophoresis, and a weak current may be passed through the electrolyte solution to conduct electricity to the skin portion and / or the composition. Examples of electrolyte solutions include water, phosphate-buffered saline (PBS), phosphate buffer, saline, MES buffer, Tris buffer, HEPES buffer, etc., and the electrolyte solution may be used alone or in combination of two or more. In this way, as long as electricity can be conducted through iontophoresis in the skin and the composition, the order of contact and conduction is not restricted.
[0037] While not limiting the present disclosure, for example, when energization is performed after the composition comes into contact with the skin, the timing of starting energization is not limited, and as shown in the test examples described later, the composition can be effectively permeated into the skin even if energization is performed simultaneously with the contact. From this, when energization is performed after the composition comes into contact with the skin, starting energization within 0 to 2 hours after the contact is preferably exemplified, more preferably 5 minutes to 1 hour after the contact, and even more preferably starting energization 10 minutes to 30 minutes after the contact is exemplified. According to the present disclosure, by using the composition of the present disclosure, the component to be delivered present on the skin and / or the component to be delivered that has permeated into the skin is pushed deeper by iontophoresis, whereby more effective permeation of the component to be delivered can be achieved. Further, according to the present disclosure, by using the composition of the present disclosure in combination with iontophoresis, transdermal absorption can be promoted, and thus this combination can be said to be useful in that it can shorten the application time of the composition of the present disclosure to the skin.
[0038] Iontophoresis may be of a direct current type, alternating current type, or pulse type, and the anode-side electrode and the cathode-side electrode may be in any form such as a rod shape, plate shape, or sheet shape (cloth shape). Examples of the electrode material include electrically conductive substances such as platinum, carbon, silver, silver chloride, copper, graphite, and lithium, and the electrode may have a plating layer of an electrically conductive substance or the like. If necessary, a voltmeter, ammeter or the like may be connected. By energizing using the anode-side electrode and cathode-side electrode connected to a power source, a weak current can be easily passed through the composition of the present disclosure applied to the skin. Usually, as long as energization is possible, the composition of the present disclosure and an electrolyte solution (such as PBS) may be used for the anode and the cathode, respectively. From the viewpoint of good usability, the composition of the present disclosure and / or the electrolyte solution may be supported on any carrier (nonwoven fabric, woven fabric, resin sheet, absorbent cotton, etc.), and this may be brought into contact with the skin and the electrodes to perform energization. The power source may be appropriately determined according to the energization means, and preferred examples include a direct current power source, a pulse current power source, and the like.
[0039] Examples of the weak current include, in the case of direct current, 0.1 to 2 mA / cm 2 approximately, preferably 0.2 to 1.5 mA / cm 2To a degree, more preferably 0.3 to 1.2 mA / cm 2 Examples of the degree, etc., are given. Furthermore, although not limited to these, the power supply voltage is exemplified as 1 to 50 V, and more preferably 5 to 10 V. The energizing time can be set appropriately depending on the type of ionic liquid used, the type of component to be delivered, the form of the composition, the application site of the composition, the expected effect, etc., and is preferably exemplified as 1 minute to 2 hours, preferably 5 minutes to 1 hour, and even more preferably 10 to 30 minutes. When energizing with a current other than DC current, each condition such as the current value can be appropriately determined according to the examples.
[0040] According to this disclosure, the delivery of the target component to the skin can be improved by using the composition of this disclosure in combination with iontophoresis. Although both ionic liquids and iontophoresis are conventionally known as methods for delivering target components to the skin, as shown in the test examples described below, it was found that when the composition of this disclosure is combined with iontophoresis, the transdermal penetration of the target component is remarkably improved compared to when ionic liquids alone or iontophoresis alone are used together with the target component. Thus, the composition of this disclosure enables even more efficient transdermal penetration of the target component.
[0041] Therefore, it can also be said that the Disclosure provides a method for treating skin with electrical current, which includes the step of applying a weak electric current by iontophoresis to skin to which the composition of the Disclosure has been applied. In this method, the composition of the Disclosure, skin, application, iontophoresis, weak electric current, electrical current, etc., are all described in the same manner as described above.
[0042] Furthermore, this means that the present disclosure provides a method for delivering a target component to the skin by iontophoresis, comprising the following steps: preparing a composition containing an ionic liquid and the target component; applying the composition so as to contact the skin; and delivering the target component into the skin by passing a weak electric current through the skin, where the ionic liquid is a salt composed of a carboxylic acid compound and an organic amine compound. In this method, the composition containing the ionic liquid and the target component is described in the same way as the composition of the present disclosure, and the composition, target component, skin, application, iontophoresis, weak electric current, etc., are all described in the same way as described above.
[0043] Furthermore, since the compositions of this disclosure are applied to the skin and used in combination with iontophoresis to promote transdermal penetration of the target component, the compositions of this disclosure may be provided in the form of a kit (e.g., a transdermal penetration promotion kit) that includes, if necessary, other components (equipment, components, etc.) such as iontophoresis electrodes, iontophoresis power supplies, and instructions for use. The instructions for use may include a URL or scan code for a webpage, and the usage procedure may be obtainable via the URL or scan code. In addition, in the kit, the compositions of this disclosure may be packaged individually or together in single-use or multi-use portions, for example, as is or supported on a carrier. These may be used individually or in combination of two or more types.
[0044] The compositions of this disclosure can promote the transdermal penetration of the delivered component. For this reason, the compositions of this disclosure can also be called compositions for electroconducting the skin, transdermal compositions, compositions for promoting skin penetration, etc., and according to this disclosure, it is possible to deliver the delivered component more efficiently through transdermal penetration. Furthermore, according to this disclosure, it is possible to exert the beneficial effects caused by the delivered component more efficiently. In addition, because the transdermal penetration efficiency is improved, according to this disclosure, the amount of the delivered component used can be reduced as needed, and this reduction also leads to a reduction in side effects caused by the delivered component.
[0045] The embodiments of this disclosure will be described in more detail below with examples, but the embodiments of this disclosure are not limited to the examples below.
[0046] Test Example 11-1. Test Procedure Test composition 1 was prepared by mixing an ionic liquid with FITC-labeled dextran (FD) (MW: 10,000) (Fluorescein isothiocyanate dextran, manufactured by Tokyo Chemical Industry Co., Ltd.). In this test, an ionic liquid consisting of lactic acid and trometamol was used as the ionic liquid, and an ionic liquid prepared by mixing these in equimolar amounts was used. Comparative composition 1 was prepared by mixing with FITC-labeled FD in the same manner, except that physiological saline (saline; 0.9% NaCl, pH 7.4) was used instead of the ionic liquid. The FD content in both test composition 1 and comparative composition 1 was 5 mg / mL.
[0047] Test composition 1 or comparative composition 1 in a 2 x 2 cm 2 100 μL of the solution was impregnated into a nonwoven fabric and applied to Wistar rats whose abdomens had been shaved. The nonwoven fabric was left in place for 2.5 hours. After that, skin samples were collected from the administration site, skin sections were prepared, and the skin penetration of FD was observed using a confocal laser microscope with FITC as the indicator. Comparative Example 1-1 was the case where test composition 1 was applied (without iontophoresis), and Comparative Example 1-2 was the case where comparative composition 1 was applied (without iontophoresis).
[0048] Separately, a nonwoven fabric impregnated with test composition 1 or comparative composition 1 was attached to a rat in the same manner, and two hours after the start of attachment, an electrode was placed on the attached area and measured at 0.34 mA / cm². 2 Iontophoresis was performed for 30 minutes at the specified current intensity (total application time 2.5 hours). Subsequently, skin samples were collected from the administration site, skin sections were prepared, and the skin penetration of FD was observed using a confocal laser microscope with FITC as the indicator. Example 1 was the case where iontophoresis was performed with test composition 1 applied, and Comparative Examples 1-3 were the cases where iontophoresis was performed with comparative composition 1 applied.
[0049] 1-2. Results The results are shown in Figure 1 (without iontophoresis) and Figure 2 (with iontophoresis). In Figure 1, "FD-ionic liquid only" shows the results for Comparative Example 1-1, and "FD-saline only" shows the results for Comparative Example 1-2. In Figure 2, "FD-ionic liquid + ItP" shows the results for Example 1, and "FD-saline" shows the results for Comparative Example 1-3.
[0050] As shown in Figure 1, in Comparative Example 1-2 (FD-saline only), fluorescence of FITC labeled with FD (the delivered component) was observed on the skin surface, indicating that FD did not penetrate the skin. In contrast, in Comparative Example 1-1 (FD-ionic liquid only), fluorescence of FITC was observed near the granular layer of the skin. The results from Comparative Examples 1-1 and 1-2 indicate that FD with a molecular weight of 10,000, which would not normally penetrate the skin, was able to penetrate the skin when used in combination with an ionic form.
[0051] Furthermore, as shown in Figure 2, in the case of Comparative Examples 1-3 (FD-saline), despite iontophoresis being performed, fluorescence of FITC labeled with FD was observed on the skin surface, similar to Comparative Examples 1-2 where iontophoresis was not performed. In contrast, as shown in Figure 2, in the case of Example 1 (FD-ionic liquid + ItP), no fluorescence of FITC was observed on the skin surface, and no significant fluorescence was observed within the skin either.
[0052] Based on these findings, in Example 1 (FD-ionic liquid + ItP), it was concluded that by coexisting the ionic liquid and FD, the FD that had permeated into the skin was further pushed to deeper layers of the skin by iontophoresis and diffused into the blood and muscle layers, resulting in the disappearance of FD from the observation area in this test example. In other words, it was suggested that combining ionic liquid and iontophoresis promotes the penetration of the target component into the skin and is useful for delivery to deeper layers of the skin, including the blood and muscle layers.
[0053] Test Example 22-1. Test Procedure: In this test, VHH antibody (MW: 18,516) was used as the target component. VHH antibody is a low molecular weight single-domain antibody that utilizes the variable region of heavy chain antibodies found in the serum of camelid animals.
[0054] Specifically, the ionic liquid or saline was mixed with the FITC-labeled VHH antibody in the same manner as in Test Example 1, except that a FITC-labeled VHH antibody was used, and the resulting solutions were designated as Test Composition 2 and Comparative Composition 2, respectively. The VHH antibody content in both Test Composition 2 and Comparative Composition 2 was 2 mg / mL. Comparative Composition 2 was then placed on a nonwoven fabric (2 x 2 cm) 2 100 μL of the nonwoven fabric was soaked into the fabric and applied to rats. The nonwoven fabric was left in place for 2 hours. After that, skin sections were prepared in the same manner as in Test Example 1, and the skin penetration of the VHH antibody was observed using a confocal laser microscope. Separately, a nonwoven fabric soaked in Test Composition 2 was applied to rats in the same manner, and 1 hour after application, 0.34 mA / cm was observed in the same manner as in Test Example 1. 2 Iontophoresis was performed for 1 hour at the specified current intensity (total application time 2 hours). Subsequently, skin sections were prepared in the same manner, and the skin penetration of the VHH antibody was observed using a confocal laser microscope. Comparative Example 2 was the case where comparative composition 2 was applied (without iontophoresis). Example 2 was the case where test composition 2 was applied and iontophoresis was performed.
[0055] 2-2. Results The results are shown in Figure 3. In Figure 3, "VHH-saline (no ItP)" shows the results of Comparative Example 2, and "VHH-ionic liquid (with ItP)" shows the results of Example 2.
[0056] As shown in Figure 3, in Comparative Example 2, fluorescence of FITC labeled with VHH was observed on the skin surface, confirming that VHH did not penetrate the skin, similar to FD. In contrast, in Example 2, no fluorescence of FITC was observed on the skin surface, but rather weak fluorescence was observed in the deeper layers of the skin. These results suggest that using a mixture of VHH and an ionic liquid, and then performing iontophoresis, allows for further penetration of the target component, VHH, into the deeper layers of the skin.
[0057] Test Example 33-1. Test Procedure Test composition 3 and comparative composition 3 were prepared in the same manner as in Test Example 2, except that the content of FITC-labeled VHH antibody in test composition 2 and comparative composition 2 was changed to 4.5 mg / mL. In the same manner as in Test Example 2, test composition 3 or comparative composition 3 was impregnated into a nonwoven fabric and attached to a rat (450 μg / rat), and the nonwoven fabric was left attached for 2 hours. Separately, a nonwoven fabric impregnated with test composition 3 in the same manner was attached to a rat, and 0.34 mA / cm was detected 1 hour after the start of attachment. 2 Iontophoresis was performed for 1 hour at the specified current intensity (total application time 2 hours). Subsequently, skin sections were prepared in the same manner as in Test Example 2, and the skin penetration of the VHH antibody was observed using a confocal laser microscope with FITC as the indicator. Comparative Example 3-1 was the case where test composition 3 was applied (without iontophoresis), Comparative Example 3-2 was the case where comparative composition 3 was applied (without iontophoresis), and Example 3 was the case where test composition 3 was applied and iontophoresis was performed.
[0058] Furthermore, test composition 4 was prepared by changing the content of FITC-labeled VHH antibody in test composition 3 to 5 mg / mL, and it was applied to rats (500 μg / rat). The same tests were conducted under conditions with and without iontophoresis. Comparative Example 4 was prepared when test composition 4 was applied (without iontophoresis), and Example 4 was prepared when test composition 4 was applied and iontophoresis was performed.
[0059] 3-2. Results are shown in Figures 4 to 7. Figure 4 shows the results without iontophoresis, with "FD-ionic liquid" showing the results when test composition 3 was used (Comparative Example 3-1), and "FD-saline" showing the results when comparative composition 3 was used (Comparative Example 3-2). Figure 5 shows the results with iontophoresis using test composition 3 (Example 3). Figure 6 shows the results without iontophoresis using test composition 4 (Comparative Example 4), and Figure 7 shows the results with iontophoresis using test composition 4 (Example 4).
[0060] When VHH was mixed with saline without iontophoresis (Comparative Example 3-2), fluorescence was observed on the skin, confirming that VHH had not penetrated into the skin. In contrast, when VHH was mixed with an ionic liquid without iontophoresis (Comparative Example 3-1), there was less fluorescence on the skin and fluorescence was observed within the skin, confirming that VHH had penetrated into the skin more effectively than when saline was used. This indicates that using an ionic liquid can promote the penetration of VHH, a component with a concentration of approximately 20,000 daltons, into the skin. Furthermore, as shown in Figure 5, when VHH was mixed with an ionic liquid and iontophoresis was performed (Example 3), the fluorescence on the skin decreased even further compared to the case without iontophoresis, and surprisingly, fluorescence was observed deep within the skin. This confirms that in Example 3, iontophoresis allowed VHH, which had penetrated into the skin with the ionic liquid, to penetrate even deeper into the skin.
[0061] Furthermore, as shown in Figure 6, when the concentration of FITC-labeled VHH antibody in the ionic liquid was changed to 5 mg / mL, penetration of VHH into the skin was observed without iontophoresis (Comparative Example 4), but high fluorescence was also observed on the skin surface. In contrast, as shown in Figure 7, when iontophoresis was added (Example 4), the fluorescence on the skin surface decreased significantly and became fainter, and it was confirmed that the fluorescence had disappeared even in the deeper layers of the skin, as observed in Figure 6 (Comparative Example 4). From these results, it was confirmed that iontophoresis allowed VHH that had penetrated into the skin with the ionic liquid to penetrate even deeper into the skin, and it was understood that transdermal absorption was significantly promoted. Although not shown in the results, in the group where VHH was mixed with saline, fluorescence was observed only on the skin surface, similar to Comparative Example 3-2, indicating that it had not penetrated into the skin.
[0062] Test Example 44-1. Test Procedure The blood concentration of the delivered component was measured. Specifically, FITC-labeled dextran (FD) (MW: 10,000) was mixed with an ionic liquid and a solvent in the same manner as described above to prepare Test Composition 5 (FD-IL). In this test, as the ionic liquids, ionic liquid ILA (triethanolamine: levulinic acid (1:1, molar ratio, water-soluble ionic liquid)) and ionic liquid ILB (diisopropanolamine: isostearic acid (1:1, molar ratio, fat-soluble ionic liquid)) were used in combination. As the solvent, medium-chain fatty acid triglyceride (trade name Panacet (registered trademark) 810 (tri(caprylic acid / capric acid) glyceryl), manufactured by NOF Corporation) was used. The content (mass ratio) of FITC-labeled FD, ILA, ILB and the solvent in Test Composition 5 was set to 0.25: 12: 80: 7.75 (total amount 200 mg). Specifically, 0.5 mg of FITC-labeled FD was weighed into a 1.5 mL tube, 24 mg of ILA was added, and the mixture was heated at 70°C until dissolved (about 5 minutes). Next, 160 mg of ionic liquid ILB was added and mixed, then 15.5 mg of the solvent was added, the mixture was heated at 70°C for 2 minutes, and mixed to prepare Test Composition 5.
[0063] Chloral hydrate (50 mg / mL in PBS) was intraperitoneally administered to rats (400 mg / kg rat, 1.6 mL / 200 g rat) for anesthesia, and the back hair of male Wistar rats (7 weeks old) was shaved using a clippers. Approximately 100 mg of Test Composition 5 was applied to a non-woven fabric (2×2 cm), which was then applied to the back-shaved rat, and the non-woven fabric was fixed with vinyl tape. The non-woven fabric was left applied for 20 minutes, 40 minutes or 60 minutes, the non-woven fabric was peeled off at the time points of 20 minutes, 40 minutes or 60 minutes after application, blood was collected from the tail vein, and the FD concentration in blood was determined (IL treatment). Further, in the same manner, after Test Composition 5 was applied for 60 minutes, the non-woven fabric was peeled off, and electrodes (2×2 cm) (cathode: FD-IL, anode: PBS) were immediately applied to the skin to perform iontophoresis (ItP) (0.34 mA / cm 2(10 min) Blood was collected from the tail vein and the FD concentration in the blood was determined (IL treatment + ItP). In this case, to prevent PBS from flowing off the skin, a nonwoven fabric soaked in PBS was applied to the skin, and electrodes were placed on the nonwoven fabric to perform ItP. Since test composition 5 is viscous and does not easily flow off the skin, test composition 5 was applied to the skin and electrodes were placed on top of it. In the following test examples, ItP was performed in the same manner as needed. The presence or absence of the nonwoven fabric did not substantially affect the results.
[0064] Blood and plasma collection were performed using the following procedure. After removing the nonwoven fabric as described above, approximately 100 μL of blood was collected from the tail vein of rats (IL treatment for 20, 40, or 60 minutes) using a pipette, and hemostasis was achieved by applying pressure to the wound on the rat's tail. The collected blood was transferred to a tube containing 10 μL of EDTA solution and mixed by inversion. After centrifugation (4°C, 3000 rpm, 10 min), 60 μL of the supernatant was taken and stored at -80°C in the dark. In the case of ItP treatment (IL treatment + ItP), blood was collected 10 minutes after ItP treatment, and the supernatant was stored in the same manner. Blood was also collected from the tail vein of rats before application of test composition 5 (before treatment), and the supernatant was stored in the same manner. Next, the obtained supernatant was allowed to thaw naturally and mixed well. 60 μL of the supernatant was diluted to 300 μL with 1×PBS(-) (5-fold dilution). Each sample was added in 100 μL x 3 portions to a 96-well plate, and fluorescence was measured using a microplate reader (Ex 485 nm, Em 535 nm). (Figure 8)
[0065] Furthermore, in rats that were treated similarly except for IL treatment, with electrodes (cathode: FD-PBS, anode: PBS) attached to the skin and ItP administered for 10 minutes, blood was collected venously and the FD concentration in the blood was determined (Control (buffer only, ItP 10 min)). (Figure 9)
[0066] Furthermore, after ItP treatment, the rats were dislocated at the cervical vertebrae to excise the treated area, and frozen sections were prepared on cryomold (Tissue-Tek® Cryomold No. 3, Sakura FineTech Japan Co., Ltd.). Next, 10 μm tissue samples were prepared on glass slides using a cryostat and observed with a confocal laser microscope. (Figure 9)
[0067] Furthermore, as mentioned above, the depth from the skin surface to the deepest dermis fluorescence was measured on the screen using a scale included with the confocal laser microscope image analysis software, for both cases where only IL treatment was performed for 60 minutes and where IL treatment for 60 minutes plus ItP treatment was performed. (Figure 10)
[0068] In this study, the mean ± standard deviation was calculated from data from three or more cases, and a t-test was used to evaluate the significance of the difference. A p-value of < 0.05 was considered statistically significant. The same procedure was followed for subsequent studies.
[0069] 4-2. Results The results are shown in Figures 8 to 10. As shown in Figure 8, plasma DF concentration increased significantly when IL treatment and ItP treatment were performed compared to when IL treatment was performed alone. Also, as can be seen from Figure 10, intradermal penetration of DF was greatly promoted when IL treatment and ItP treatment were performed compared to when IL treatment was performed alone. From this, it was found that combining IL treatment and ItP treatment can effectively promote the transdermal penetration of the target component compared to when IL treatment is performed alone.
[0070] Furthermore, as shown in Figure 9, when only IL treatment was performed (without ItP treatment), the plasma DF concentration was hardly higher than the plasma DF concentration before IL treatment (time 0 minutes, i.e., no IL treatment, no ItP treatment). Therefore, it could be concluded that the transdermal penetration effect of the delivered component by IL treatment alone was very poor. Similarly, as shown in Figure 10, when ItP treatment was performed without IL treatment, the plasma DF concentration was equivalent to the plasma DF concentration before ItP treatment (time 0 minutes, i.e., no IL treatment, no ItP treatment). Therefore, it could be concluded that the transdermal penetration effect of the delivered component by ItP treatment alone was very poor. Thus, from these results, although improvement in the transdermal penetration of the delivered component could not be expected even when IL treatment and ItP treatment were combined, surprisingly, the transdermal penetration of the delivered component was effectively promoted by combining IL treatment and ItP treatment.
[0071] Test Example 55-1. Test Procedure The tests were conducted using IL2-1 to IL2-5 (test compositions 6 to 10) shown in Figure 11 as the compositions of this disclosure. In Figure 11, the "active ingredient" is FITC-labeled dextran (FD) used in Test Example 4, and "medium-chain fatty acid triglyceride" (trade name Panacete® 810, manufactured by NOF Corporation) was used as a solvent. In Figure 11, all components other than the "active ingredient" and "medium-chain fatty acid triglyceride" are components of the ionic liquid. According to Figure 11, IL2-1 to IL2-5 were prepared as follows.
[0072] IL2-1 (Test Composition 7): Ionic liquids 2-1A (IL2-1A, triethanolamine:lactic acid (1:1 molar ratio)), 2-1B (IL2-1B, triisopropanolamine:decanoic acid (capric acid) (1:1 molar ratio)), 2-1C (IL2-1C, triethanolamine:salicylic acid (1:1 molar ratio)), and 2-1D (IL2-1D, triisopropanolamine:lactic acid (1:1 molar ratio)) were prepared. Then, FD was mixed with each ionic liquid. After that, a solvent was added and mixed.
[0073] IL2-2 (Test Composition 7): Ionic liquids 2-2A (IL2-2A, triethanolamine: isostearic acid (1:1 molar ratio)), 2-2B (IL2-2B, triethanolamine: lactic acid (1:1 molar ratio)), 2-2C (IL2-2C, triisopropanolamine: lactic acid (1:1 molar ratio)), and 2-2D (IL2-2D, diisopropanolamine: oleic acid (1:1 molar ratio)) were prepared. Then, FD was mixed with each ionic liquid. After that, a solvent was added and mixed.
[0074] IL2-3 (Test Composition 8): Ionic liquids 2-3A (IL2-3A, triethanolamine:leprine acid (1:1 molar ratio)), 2-3B (IL2-3B, triisopropanolamine:decanoic acid (1:1 molar ratio)), 2-3C (IL2-3C, triethanolamine:salicylic acid (1:1 molar ratio)), 2-3D (IL2-3D, diisopropanolamine:isostearic acid (1:1 molar ratio)), and 2-3E (IL2-3E, triisopropanolamine:leprine acid (1:1 molar ratio)) were each prepared. Then, FD was mixed with each ionic liquid. After that, a solvent was added and mixed.
[0075] IL2-4 (Test Composition 9): Ionic liquids 2-4A (IL2-4A, triisopropanolamine:decanoic acid (1:1 molar ratio)), 2-4B (IL2-4B, triethanolamine:salicylic acid (1:1 molar ratio)), 2-4C (IL2-4C, diisopropanolamine:isostearic acid (1:1 molar ratio)), 2-4D (IL2-4D, triisopropanolamine:salicylic acid (1:1 molar ratio)), and 2-5E (IL2-5E, diisopropanolamine:decanoic acid (1:1 molar ratio)) were each prepared. Then, FD was mixed with each ionic liquid. After that, a solvent was added and mixed.
[0076] IL2-5 (Test Composition 10): Ionic liquid 2-5A (IL2-5A, triisopropanolamine: isostearic acid (1:1 molar ratio)) and ionic liquid 2-5B (IL2-5B, triethanolamine: lactic acid (1:1 molar ratio)) were prepared separately. Then, FD was mixed with IL2-5A, and then with IL2-5B. After that, a solvent was added and mixed.
[0077] Following the procedure shown in Figure 12, IL treatment (attaching a nonwoven fabric coated with one of the test compositions 6-10 to the rat) was performed for 60 minutes in the same manner as in Test Example 4. After removing the nonwoven fabric, electrodes (2 x 2 cm) (cathode: one of the test compositions 6-10, anode: PBS) were immediately attached to the skin, and ItP was performed (0.34 mA / cm²). 2Blood was collected from the tail vein (at 10 min) and the plasma FD concentration was determined. Blood was collected a total of seven times from the start of the experiment (0 min in Figure 12).
[0078] 5-2. Results The results are shown in Figure 12. As shown in Figure 12, compared to the case where only IL treatment was performed (up to 60 minutes from the start of the test), the plasma FD concentration increased significantly when IL treatment and ItP treatment were used in combination. This also indicates that combining IL treatment and ItP treatment can effectively promote the transdermal penetration of the delivered component.
[0079] Furthermore, using FD-IL as the ionic liquid, the same procedure was followed by IL treatment for 60 minutes, then ItP treatment for 10 minutes. Blood samples were then taken, and the FD concentration in the plasma was checked. As shown in Figure 13, it was found that even when using FD-IL, combining IL treatment and ItP treatment effectively promotes the transdermal penetration of the target component.
[0080] This test example shows that combining IL treatment and ItP treatment results in a synergistic and superior penetration effect compared to using IL treatment alone or ItP treatment alone.
[0081] Test Example 66-1. Test Procedure Test composition 11 was prepared by mixing FITC-labeled dextran (FD) (MW: 10,000) (Fluorescein isothiocyanate dextran, Sigma-Aldrich) with an ionic liquid (IL) and a solvent. In this test, ionic liquid A (ILA, triethanolamine:levulinic acid (5.26:6.74 w / W ratio), water-soluble ionic liquid) and ionic liquid B (ILB, diisopropanolamine:isostearic acid (25.25:54.48 w / W), lipid-soluble ionic liquid) were used as the ionic liquids. FD was mixed with ILA, and then with ILB. After that, medium-chain triglyceride (trade name Panaceto® 810, manufactured by NOF Corporation) was added and mixed. Specifically, 0.5 mg of FD was weighed into a 1.5 mL tube, 24 mg of ILA was added, and the mixture was heated at 70°C until dissolved (approximately 5 minutes). Next, 160 mg of ILB was added and mixed, and then 15.5 mg of solvent was added and heated at 70°C for 2 minutes, and the mixture was mixed to prepare test composition 11. Comparative composition 4 was prepared by mixing with FITC-labeled FD in the same manner, except that physiological saline (saline; pH 7.4) was used instead of ionic liquid.
[0082] Test composition 11 or comparative composition 4 in a 2 x 2 cm area. 2 A 20 μL solution was soaked into a nonwoven fabric and attached to ICR mice whose abdomens had been shaved. Thirty minutes after attachment, an electrode was placed on the attachment site and measured at 0.34 mA / cm². 2 Iontophoresis (ItP) was performed for 30 minutes at the specified current intensity (total application time: 1 hour). Subsequently, blood was collected from the inferior vena cava and plasma was recovered. The amount of FD transferred into the bloodstream 1 hour after transdermal administration to mice was evaluated using the fluorescence intensity of FITC of FD as an indicator.
[0083] Example 5 (IL-ItP in Figure 14) was the case where test composition 11 was applied and ItP was used, and Comparative Example 5-1 (IL in Figure 14) was the case where test composition 11 was applied for 1 hour (without ItP). Comparative Example 5-2 (Saline + ItP in Figure 14) was the case where comparative composition 4 was applied and ItP was used, and Comparative Example 5-3 (Saline in Figure 14) was the case where comparative composition 4 was applied for 1 hour (without ItP).
[0084] 6-2. Results The results are shown in Figure 14. In the cases of IL alone (Comparative Example 5-1), Saline alone (Comparative Example 5-3), and Saline + ItP (Comparative Example 5-2), almost no fluorescence of FD was observed in the plasma. In contrast, when IL was applied and ItP was used in combination (Example 5; IL-ItP), significant blood transfer of FD was observed. This result suggests that FD, with a molecular weight of 10,000, which would not normally penetrate the skin, penetrated the skin when combined with the ionic liquid and ItP, and then entered the systemic circulation from the capillaries in the dermis.
[0085] Test Example 77-1. Test Procedure: In this test, an ionic liquid was prepared using FD with a molecular weight of 70 kDa in the same manner as for test composition 11, and this was designated as test composition 12.
[0086] In the same manner as described above, a nonwoven fabric impregnated with test composition 12 was attached to a rat, and 30 minutes after the start of application, an electrode was placed on the attached area and measured at 0.34 mA / cm². 2 ItP was performed for 30 minutes at the specified current intensity (total application time 1 hour). Blood was then collected from the inferior vena cava and plasma was recovered. The amount of FD transferred into the blood 1 hour after transdermal administration to mice was evaluated using the fluorescence intensity of FITC of FD as an indicator. Example 6 (IL + ItP in Figure 15) was the case where test composition 12 was applied and treated with ItP, and Comparative Example 6-1 (IL in Figure 15) was the case where test composition 12 was applied for 1 hour (without ItP).
[0087] Furthermore, after the above treatment, the mice were dislocated at the cervical vertebrae and the treated area was excised, and frozen sections were prepared on cryomold (Tissue-Tek® Cryomold No. 3, Sakura Finetech Japan Co., Ltd.). Next, 10 μm tissue samples were prepared on glass slides using a cryostat and observed with a fluorescence microscope (Figure 16). In Figure 16, "Contl" indicates the observation results for mice that were not treated with the above composition or ItP treatment.
[0088] 7-2. Results As shown in Figure 15, when IL and ItP were used in combination, FD was significantly transferred into the bloodstream compared to when IL was used alone. This result suggests that FD with a molecular weight of 70,000, which would not normally penetrate the skin, penetrated the skin when combined with ionic liquid and ItP, and was transferred to the systemic circulation via the capillaries in the dermis, similar to FD with a molecular weight of 10,000.
[0089] Furthermore, as shown in Figure 16, when IL alone was used, fluorescence of FD-labeled FITC was observed in the skin epidermis. In contrast, when IL + ItP was used, fluorescence of FITC was observed even in the deeper layers of the skin, providing results that support those of Test Example 7.
[0090] Test Example 88-1. Test Procedure: In this test example, the test was conducted in the same manner as in Test Example 7, except that the application time of the ionic liquid before iontophoresis and the time of iontophoresis performed afterward were changed. The effect of the application and iontophoresis times on transdermal absorption was investigated.
[0091] In the same manner as in Test Example 7, a nonwoven fabric impregnated with test composition 12 was attached to a rat, and 5 minutes after the start of application, an electrode was placed on the attached area and measured at 0.34 mA / cm². 2ItP was performed for 15 minutes at the specified current intensity (total application time 20 minutes). Blood was then collected from the inferior vena cava and plasma was recovered. The amount of FD transferred into the blood 20 minutes after transdermal administration to mice was evaluated using the fluorescence intensity of FITC of FD as an indicator. The results when test composition 12 was applied and treated with ItP are shown in Figure 17 as IL + ItP, and the results when test composition 12 was applied for 20 hours (without ItP) are shown in Figure 17 as IL. In addition, comparative composition 5 was prepared by mixing it with FITC-labeled FD in the same manner except that physiological saline (saline; pH 7.4) was used instead of ionic liquid, and the same procedure as when using test composition 12 was followed: application only (Saline in Figure 17), application and ItP treatment (Saline + ItP in Figure 17).
[0092] Furthermore, after the above treatment, the mice were dislocated at the cervical vertebrae and the treated area was excised, and frozen sections were prepared on cryomold (Tissue-Tek® Cryomold No. 3, Sakura Finetech Japan Co., Ltd.). Next, 10 μm tissue samples were prepared on glass slides using a cryostat and observed with a fluorescence microscope (Figure 18). In Figure 18, "Contl" indicates the observation results for mice that did not undergo the above treatment.
[0093] 8-2. Results As shown in Figure 17, compared to the case with IL alone, the combination of IL and ItP (IL+ItP) resulted in significantly greater transfer of FD into the bloodstream. This result suggests that, similar to FD with a molecular weight of 10,000, FD with a molecular weight of 70,000, which would not normally penetrate the skin, penetrated the skin when combined with ionic liquid and ItP, and was transferred to the systemic circulation via capillaries in the dermis. In this test example, the application time for IL was 5 minutes and the time for ItP was 15 minutes, which was shorter than in Test Example 7. However, the transfer of FD into the bloodstream was observed to the same extent as in Test Example 7 with IL+ItP, suggesting that even a short time is sufficient to significantly enhance the intradermal penetration of FD.
[0094] Furthermore, as shown in Figure 18, fluorescence of FD-labeled FITC was observed in the skin epidermis when Saline (including FD) was used alone, and when IL (including FD) was used alone. Similarly, fluorescence of FD-labeled FITC was also observed in the skin epidermis when Saline (including FD) + ItP was used. In contrast, when IL + ItP was used, fluorescence of FITC was observed even in the deeper layers of the skin, providing results that support those shown in Figure 17.
[0095] Test Example 99-1. Test Procedure In this test example, the effect of iontophoresis time was investigated by fixing the application time of the ionic liquid before iontophoresis to 5 minutes and varying the time of iontophoresis performed thereafter. Test composition 13 was prepared in the same manner as test composition 12, except that a 10 kDa FD was used. Next, a nonwoven fabric impregnated with test composition 13 was applied to a rat in the same manner as described above, and 5 minutes after the start of application, an electrode was placed on the applied area and measured at 0.34 mA / cm². 2 ItP was administered at current intensities of 5 minutes, 10 minutes, and 15 minutes, respectively (total application time was 10 minutes, 15 minutes, and 20 minutes, respectively). Blood was then collected from the inferior vena cava, and plasma was recovered. The amount of FD transferred into the bloodstream 20 minutes after transdermal administration to mice was evaluated using the fluorescence intensity of FITC of FD as an indicator. (Figure 19)
[0096] Furthermore, after ItP treatment, the mice were dislocated at the cervical vertebrae to excise the treated area, and frozen sections were prepared on cryomold (Tissue-Tek® Cryomold No. 3, Sakura Finetech Japan Co., Ltd.). Next, 10 μm tissue samples were prepared on glass slides using a cryostat and observed with a fluorescence microscope. (Figure 20)
[0097] 9-2. Results As shown in Figure 19, when we investigated by changing the duration of ItP treatment, we found no significant difference in the blood transfer of FD depending on the ItP treatment time. Under these experimental conditions, it was found that even with ItP for about 5 minutes, combining it with IL enhanced the intradermal penetration of FD with a molecular weight of about 10,000. Furthermore, as shown in Figure 20, even with ItP for about 5 minutes, intradermal penetration of FD was observed, providing results that support the results shown in Figure 19.
[0098] Test Example 1010-1. Test Procedure In this test example, an ointment formulation (test composition 14) containing FD with a molecular weight of 10,000 and an ionic liquid was prepared, and it was confirmed whether the intradermal penetration of FD could be enhanced when this was applied to the skin and then iontophoresis was performed.
[0099] Test composition 14 in a 2 x 2 cm 2 50 μL of the solution was soaked into a nonwoven fabric and applied to ICR mice whose abdomens had been shaved. The mass ratio of FD, ILA, and ILB in test composition 14 was 0.2 : 0.8 : 3.67. ILA and ILB are ionic solutions obtained by mixing a carboxylic acid compound and an organic amine compound in equimolar amounts, respectively. The mass ratio of FD, ILA, ILB, and excipients (light anhydrous silicic acid, gelling hydrocarbon) in the ointment preparation was 0.2 : 0.8 : 3.67 : 0.25 : 95.08 (total amount 100 mg). FD was weighed out to 250 μg and applied to the mouse skin by finger. Five minutes after application or application began, an electrode was placed on the application or application site and measured at 0.34 mA / cm². 2 Iontophoresis (ItP) was performed for 30 minutes at the specified current intensity (total application time: 35 minutes). Blood was then collected from the inferior vena cava and plasma was recovered. The amount of FD transferred into the bloodstream 35 minutes after transdermal administration (patch or application) to mice was evaluated using the fluorescence intensity of FITC of FD as an indicator.
[0100] Furthermore, after ItP treatment, the mice were dislocated at the cervical vertebrae to excise the treated area, and frozen sections were prepared on cryomold (Tissue-Tek® Cryomold No. 3, Sakura Finetech Japan Co., Ltd.). Next, 10 μm tissue samples were prepared on glass slides using a cryostat and observed with a fluorescence microscope (Figure 22). In Figure 22, "Contl" indicates the observation results for mice that did not undergo the above treatment.
[0101] 10-2. Results As shown in Figure 21, when ItP was used in combination with the ointment formulation (ointment + ItP in the figure), significantly higher plasma FD fluorescence was observed compared to the ointment formulation group alone (without ItP (ointment in the figure)). Note that in Figure 21, IL + ItP and IL are compositions prepared in the same manner as the ointment formulation, except that no excipients were used.
[0102] Furthermore, as shown in Figure 22, when ointment formulations were used in combination with ItP (ointment + ItP in the figure), FD penetrated deeper into the epidermis compared to the ointment formulation group alone (ointment in the figure).
[0103] Test Example 1111-1. Test Procedure In this test, semaglutide (MW: 4113.6), a GLP-1 receptor agonist, was used as the delivered component. Semaglutide is a compound that can induce insulin secretion in a glucose concentration-dependent manner and is known to have an effect of suppressing the rise in blood glucose levels.
[0104] Specifically, a test composition (test composition 15) was prepared by mixing semaglutide with an ionic liquid. In this test, two ionic liquids were prepared: ionic liquid IL11-A (2.63:3.37 W / W (approximately 1:1.6 molar ratio)), consisting of levulinic acid and triethanolamine (water-soluble ionic liquid), and ionic liquid IL11-B (12.76:27.24 W / W (approximately 1:1 molar ratio)), consisting of isostearic acid and diisopropanolamine (lipid-soluble ionic liquid). After dissolving semaglutide in ionic liquid IL11-A, ionic liquid IL11-B was mixed in such a ratio of ionic liquid IL11-A:ionic liquid IL11-B = 3:20 (W / W) to prepare a semaglutide-containing ionic liquid. At this time, in order to thoroughly mix the ionic liquids IL11-A and IL11-B, medium-chain fatty acid triglycerides (trade name Panasete®) were added as a solvent to a concentration of 3 w / w% in test composition 15. The semaglutide content in test composition 15 was 5 mg / mL.
[0105] Test composition 15 in a 2 x 2 cm 2 50 μL of the solution was soaked into a nonwoven fabric and attached to ICR mice (fasted overnight before the experiment) whose abdomens had been shaved. An electrode plate was placed on the attachment site, and 0.34 mA / cm² was applied. 2Iontophoresis (ItP) was performed for 10 minutes at the specified current intensity. Afterward, the electrodes and non-woven fabric were removed, and a glucose solution was orally administered to the mouse at a glucose level of 2.0 g / kg relative to its body weight. Blood samples were collected from the mouse's tail at 0, 15, 30, 45, 60, 90, and 120 minutes after oral glucose loading, and blood glucose levels were measured. This was designated as Example 7.
[0106] As control groups, glucose loading and blood glucose levels were measured in the same manner as described above for three groups of mice: an untreated group that only underwent shaving (Comparative Example 7-1), a group that did not undergo ItP but had test composition 15 applied for 10 minutes (Comparative Example 7-2), and a group that had test composition 15 applied for 120 minutes (Comparative Example 7-3).
[0107] 11-2. Results The results are shown in Figure 23. In Figure 23, "Semaglutide-ionic liquid + ItP (applied for 10 minutes)" is Example 7, "Control" is Comparative Example 7-1, "Semaglutide-ionic liquid (applied for 10 minutes)" is Comparative Example 7-2, and "Semaglutide-ionic liquid (applied for 120 minutes)" is Comparative Example 7-3.
[0108] As shown in Figure 23, in Comparative Example 7-1, the untreated group, blood glucose levels increased over 60 minutes after glucose loading, and then gradually decreased over 120 minutes. In Comparative Example 7-2, the group that applied the test composition 15 for 10 minutes before glucose loading showed an increase in blood glucose levels after glucose loading, but the increase was more gradual compared to Comparative Example 7-1. This was thought to be due to the absorption of semaglutide through the skin by the ionic liquid. Furthermore, in Comparative Example 7-3, the group that applied the test composition for 120 minutes before glucose loading showed almost no increase in blood glucose levels after glucose loading. This was thought to be due to an increase in the amount of semaglutide absorbed transdermally by the ionic liquid as the application time was extended. In contrast, in Example 7, when the test composition 15 was applied 10 minutes before glucose loading and iontophoresis (ItP) was performed simultaneously, almost no increase in blood glucose levels was observed even after glucose loading. Thus, the inhibitory effect on the increase in blood glucose levels in Example 7 was superior to that of Comparative Example 7-3, in which the test composition 15 was applied for 120 minutes. This result indicates that the effect of ionic liquids on promoting the transdermal absorption of semaglutide is significantly enhanced when used in combination with ItP, allowing for the transdermal absorption of a large amount of semaglutide in a short time. In other words, it was shown that using ionic liquids and ItP in combination can promote the transdermal absorption of the target component and also lead to a reduction in administration time.
Claims
1. A composition containing an ionic liquid and a component to be delivered, for use in combination with iontophoresis, wherein the ionic liquid is a salt composed of a carboxylic acid compound and an organic amine compound.
2. The composition according to claim 1, wherein the carboxylic acid compound is at least one selected from the group consisting of hydroxy acids having 3 to 7 carbon atoms, aliphatic monocarboxylic acids having 4 to 20 carbon atoms, keto acids having 3 to 7 carbon atoms, aromatic monocarboxylic acids having 6 to 12 carbon atoms, dicarboxylic acids having 3 to 9 carbon atoms, and tricarboxylic acids having 6 to 12 carbon atoms, and the organic amine compound is an alkanolamine having 2 to 9 carbon atoms.
3. The composition according to claim 1, wherein the carboxylic acid compound is at least one selected from the group consisting of lactic acid, sorbic acid, capric acid, lauric acid, myristic acid, stearic acid, isostearic acid, oleic acid, salicylic acid, and levulinic acid.
4. A method for delivering a target component to the skin by iontophoresis, comprising the following steps: preparing a composition containing an ionic liquid and a target component, applying the composition to the skin in contact with the skin, and delivering the target component into the skin by passing a weak electric current through the skin, wherein the ionic liquid is a salt composed of a carboxylic acid compound and an organic amine compound.
5. A method for electrotherapy of the skin, comprising the following steps: a step of applying a weak electric current by iontophoresis to skin to which a composition containing an ionic liquid and a component to be delivered has been applied, wherein the ionic liquid is a salt composed of a carboxylic acid compound and an organic amine compound.
